Prospective Cohort Study on Fuzheng Yangxin Prescription For Rapid Rehabilitation of Patients With Qi-Yin Deficiency Syndrome After Coronary Artery Bypass Grafting

NCT06961136 · clinicaltrials.gov ↗

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Coronary Artery Bypass

Interventions

DRUG: Fuzheng Yangxin prescription
DRUG: placebo

Sponsor

Peking University Third Hospital